TTP889
- Generic Name
- TTP889
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
TTP889, an orally bioavailable selective inhibitor of the intrinsic coagulation pathway, is being developed as an anticoagulant for the treatment of thromboembolic disorders. TTP889 is the only known selective small molecule inhibitor of Factor IX, a key enzyme of the intrinsic pathway of the blood coagulation system. TTP889 has proven to be effective in pre...
- Indication
Investigated for use/treatment in blood (blood forming organ disorders, unspecified), cardiac surgery, and venous thromboembolism.
- Associated Conditions
- -
- Associated Therapies
- -
Left Ventricular Assist Device (LVAD) Specialized Centers of Clinically Orientated Research (SCCOR) Coagulation - Acute Intrinsic Pathway Antagonist (IPA)
- First Posted Date
- 2009-05-28
- Last Posted Date
- 2011-06-27
- Lead Sponsor
- vTv Therapeutics
- Target Recruit Count
- 2
- Registration Number
- NCT00909298
- Locations
- 🇺🇸
Mount Sinai School of Medicine, New York, New York, United States
🇺🇸New York Presbyterian Hospital / Columbia University Medical Center, New York, New York, United States
🇺🇸Providence Sacred Heart Medical Center and Children's Hospital, Spokane, Washington, United States
Factor IX Inhibition in Thrombosis Prevention (The FIXIT Trial)
- Conditions
- First Posted Date
- 2005-07-13
- Last Posted Date
- 2009-06-03
- Lead Sponsor
- vTv Therapeutics
- Target Recruit Count
- 300
- Registration Number
- NCT00119457
- Locations
- 🇩🇰
Horsholm Hospital, Horsholm, Denmark
🇳🇴Orthopedics, Alesund Sykehus, Alesund, Norway
🇸🇪Ortoped kliniken, Sahlgrenska Universitetssjukhus, Molndal, Sweden
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.